Dear visitor

this is the website of a previous conference,
you can visit the actual conference here.

Sehr geehrter Besucher

Sie befinden sich auf der Webseite eines früheren Kongresses.
Sie können den aktuellen Kongress hier besuchen.

Current Congress

ePosters only

ePoster Submission

Submission deadline was Tuesday, 17 October 2017, CET 23.59h

Please note that abstracts accepted as "ePosters only" will be displayed on terminals during the congress. However they will not be presented at a specific session. In addition all ePosters will be available on the ECTRIMS Online Library.

For your references please find below the ePoster numbers.

ePoster numbers

ePoster Number Abstract Title First name Last name
EP1274 Multiple Sclerosis, Depression and Voice: a new tool for diagnosis? Laetitia Bruckert
EP1275 Comparison of Central Vein Detection in MS at 1.5T, 3T and 7T Alix Fechner
EP1276 Comparison between proton density and T2 weighted sequences for detection of cervical cord lesions in Multiple Sclerosis Masoume Nazeri
EP1277 Prognostic factors for multiple sclerosis in patients with isolated spinal syndromes Gloria Dalla Costa
EP1278 Clinical, investigational and outcome profile of Acute Myelitis in the city of Kolkata, India Tapas K. Banerjee
EP1279 Evaluation of the predictive value of three serum and CSF Biomarkers for the development of clinically definite multiple sclerosis (CDMS) following an initial clinically isolated demyelinating event (CIS) Nour Eddine Yaghmour
EP1280 Anti-MOG-IgG associated syndromes: report of 22 cases Sara Mariotto
EP1281 Cerebrospinal fluid CD4+/CD8+ ratio in diagnosing neurosarcoidosis Clas Malmeström
EP1282 Changes in the profile of patients with multiple sclerosis over the last 30 years due to evolution of diagnostic criteria Anna Czlonkowska
EP1283 The MRZ reaction in rheumatological disorders with CNS involvement and primary CNS lymphoma Tilman Hottenrott
EP1284 Role of Visual Evoked Potentials in Spatial dissemination for Multiple Sclerosis Diagnosis Giuseppe Fenu
EP1285 Integrin and IL-16/IL-23 biomarker clusters differentiate AQP4-IgG+ NMO spectrum disorders, relapsing-remitting MS and healthy controls Helle H. Nielsen
EP1286 Frequency of anti-AQP4 and anti-MOG antibody positivity in patients with demyelinating diseases in Rio de Janeiro / Brazil Vanderson Carvalho Neri
EP1287 Serum aquaporin-4-IgG and MOG-IgG in patients with an initial demyelinating event: protocol and preliminary results of an Italian prospective multicentre study Riccardo Orlandi
EP1288 Detection of anti MOG antibodies in Demyelinating disorders of the central nervous system (CNS) Arianna Sala
EP1289 Which treatment strategies for highly refractory forms of Neuro-Behçet disease? Frédéric London
EP1290 Neuromyelitis optica spectrum disorders with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies: clinical and paraclinical characteristics in Algerian patients Melissa Bouzar
EP1291 Not all optic neuritis are multiple sclerosis: Drusen and paraneoplastic autoimmune disease as cause of optic neuropathy in young people Juan Luis Ruiz Peña
EP1292 Brainstem syndrome and longitudinally extensive transverse myelitis (LETM) as first manifestation of Adult T-Cell Leukemia/Lymphoma (ATLL) Ana Beatriz Ayroza Galvão Ribeiro Gomes
EP1293 In-vivo Axon diameter dynamics in Clinically Isolated Syndrome: A powerful biomarker in early diagnosis of MS Assaf Horowitz
EP1294 Misdiagnosis of multiple sclerosis and common alternate diagnoses Marwa Kaisey
EP1295 Detailed characterization of pain and depression in NMOSD: prevalence, clinical features, management and impact on quality life Ilya Ayzenberg
EP1296 Antinuclear antibodies as potential markers of disability and recurrence in patients with Neuromyelitis optica Azucena De León Murillo
EP1297 Maintenance therapeutic plasma exchange in patients with neuromyelitis optica spectrum disorders Irena P. Dujmovic Basuroski
EP1298 Clinical Course and Prognosis of NeuroMyelitis Optica Spectrum Disorder in a Moroccan Cohort Anas Bennis
EP1299 Is there any relation between tumefactive demyelinating lesions and antibodies against MOG and AQP4? Ayse Altintas
EP1300 Genetic Polymorphism of Aquaporin-4 Gene in Neuromyelitis Optica Spectrum Disorder Arman Cakar
EP1301 Neuromyelitis optica phenotype associated with anti-TNF therapy in psoriatic arthritis Mateus Boaventura
EP1302 Atypical Multiple Sclerosis and Idiopathic Inflammatory Demyelinating Diseases in a series of 74 consecutive cases Pierre Labauge
EP1303 Atypical myelitis of Multiple Sclerosis: description of a French cohort Carole Lambert
EP1304 Visual pathway changes in children with multiple sclerosis and acquired demyelinating disorders Giulia Longoni
EP1305 Gut microbiota function and relapse risk in pediatric multiple sclerosis (MS): using predictive metagenomics Helen Tremlett
EP1306 Physical activity and its association with white matter integrity and cognitive efficiency in pediatric-onset multiple sclerosis Elisea De Somma
EP1307 Serum tryptophan is associated with paediatric multiple sclerosis onset and disease activity Bardia Nourbakhsh
EP1308 Epidemiological aspects of childhood MS in Iran Maryam Sharifian Dorche
EP1309 CSF kappa free light chains in early-onset multiple sclerosis Andreja Emersic
EP1310 Natalizumab treatment in pediatric multiple sclerosis patients does not affect pubertal and developmental genes Michael Gurevich
EP1311 Five-year follow-up of pediatric onset Neuromyelitis Optica Spectrum Disorders (NMOSD) Renata Paolilo
EP1313 Body mass index Trajectories in paediatric multiple sclerosis James Nicholas Brenton
EP1314 Pediatric Neuromyelitis Optica is more severe than pediatric Multiple Sclerosis in Brazilian patients Manuela Oliveira Fragomeni
EP1315 Educational Outcomes in Pediatric Multiple Sclerosis Wendy Vargas
EP1316 Ocular flutter as presenting manifestation of Pediatric Multiple Sclerosis with positive anti-MOG antibodies – A case report Marianthi Breza
EP1317 Case studies of Rituximab in pediatric patients with multiple sclerosis Agata Ulatowska
EP1318 Depression and Physical Performance in Pediatric onset MS patients Mary Rensel
EP1319 Longitudinal Evaluation of Cognitive, Academic, and Adaptive Functioning in Pediatric MS Karen D. Evankovich
EP1320 characteristics of pediatric multiple sclerosis in the west of algeria Zahira Barka Bedrane
EP1321 Risk of transition to secondary progressive multiple sclerosis and accumulation of disability in progressive multiple sclerosis are not influenced by current therapies Carmen Alcalá
EP1322 The Bayesian Risk Estimate at Onset (BREMSO) correlates with cognitive and physical disability in patients with early Multiple Sclerosis Marianne Said
EP1323 Prognostic value of cerebrospinal fluid kappa and lambda free light chains in clinically isolated syndrome in Argentina María S. Sáez
EP1324 Prognostic factors related to the severity of multiple sclerosis in the Japanese population Hideki Houzen
EP1325 Utilizing the Topographical Model of MS to Identify Leading Indicators of Progression Stephen C. Krieger
EP1326 Time to, and rate of secondary progression in patients with multiple sclerosis: results of a systematic search Jennie Medin
EP1327 Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis – the PaSiMS II study Gabriel Bsteh
EP1328 Clinical Presentation of clinically isolated syndrome (CIS); a long term follow up study in Iranian patients Maryam Sharifian Dorche
EP1329 The effect of exclusive breastfeeding on postpartum Multiple Sclerosis relapses Navideh Sahebi Vaighan
EP1330 The incidence of cognitive impairment among Hungarian relapsing-remitting multiple sclerosis patients Dániel Sandi
EP1331 The prevalence of Multiple Sclerosis in the Province of Padua, North-East Italy, is significantly higher in urban areas and associates with air quality Fabio Tadeo
EP1332 Autoimmune diseases in multiplex MS families in the Netherlands Julia Y. Mescheriakova
EP1333 Rising Prevalence of Multiple Sclerosis in Mexico: A New Estimation Based on a Multicenter Registry and Sanitary Administrative Data Erwin Chiquete
EP1334 Temporal trend in the disease activity of multiple sclerosis in Korea Hyun-June Shin
EP1335 Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France: data from the OFSEP database over the period 1996-2017 Emmanuelle Leray
EP1336 Familial Multiple Sclerosis: a Portuguese hospital-based cohort study Daniela Sofia Ferro
EP1337 Computer-based registry for central nervous system demyelinating disease in Brazil - REDONE databank Doralina G. Brum
EP1338 Neuromyelitis optica spectrum Disorder in Tehran, Iran Sharareh Eskandarieh
EP1339 Characteristics and therapeutic management of patients with relapsing-remitting multiple sclerosis – Data from a French multiple sclerosis population-based registry (the Multiple Sclerosis Registry in Lorraine Region) Jonathan Epstein
EP1340 Prevalence of Multiple Sclerosis in Quito, Ecuador Edgar Patricio Correa Díaz
EP1341 α-Linolenic acid (ALA) serum levels are associated with reduced MRI activity in a prospective cohort of MS patients Øivind Torkildsen
EP1342 Late onset multiple esclerosis Gabriel Valero López
EP1343 Comorbidity prevalence in a multiple sclerosis center Clara Zanchi
EP1344 Prevalence of multiple sclerosis in San Vicente del Raspeig, Spain: a population-based study Natalia Perez-Carmona
EP1345 Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location Peter Alping
EP1346 Characterization of the Hispanic Male Multiple Sclerosis Patient in Puerto Rico Cristina Rubi
EP1347 Bayesian spatio-temporal mapping of Multiple Sclerosis (MS) incidence ratio in Fars Province , southern Iran Maryam Sharifian Dorche
EP1348 Incidence and prevalence of multiple sclerosis in Saint-Petersburg Maria Shumilina
EP1350 Demographic and clinical feature among patients with neuromyelitis optica in Iran Sharareh Eskandarieh
EP1351 Care consumption of multiple sclerosis patients in France: an analysis of health insurance administrative databases using multichannel sequence analysis from 2007 to 2013 Jonathan Roux
EP1352 Prevalence and prognosis of multiple sclerosis in a cohort of Algerian patients Zahira Barka Bedrane
EP1353 Gender effect on cortical thickness measurements in primary progressive and relapsing remitting multiple sclerosis patients: a paired cross sectional study Keshet Pardo
EP1354 Brain MRI activity in Multiple Sclerosis(MS) before and after pregnancy Maryam Sharifian Dorche
EP1355 Long Term Effect of Delaying Disease Modifying Therapy in Patients with Multiple Sclerosis due to Pregnancy Planning Seraj Makkawi
EP1356 Differential gene expression in men and women with multiple sclerosis compared with healthy individuals Hannah-Marie Laigaard
EP1357 Fertility, Maternal and Pediatric Development Outcomes: Interim Report from the PREG-MS Registry Tatenda D. Mahlanza
EP1358 Inflammatory active peri- and postmenopausal patients in multiple sclerosis – a crosssectional study Birte Elias-Hamp
EP1359 Pregnancy outcome and change in lymphocyte subset in peripheral blood in Japanese patients with multiple sclerosis after assisted reproductive treatment Yuko Shimizu
EP1360 Levels of Serum Anti-müllerian hormone in women with relapsing-remitting multiple sclerosis Monika Svobodova
EP1361 Study on the adherence to the Spanish Neurological Society consensus guidelines on the treatment of multiple sclerosis generalized spasticity in Spanish multiple sclerosis units Jose Maria O. Prieto
EP1362 Balance and gait impairment at the early stages of Multiple Sclerosis Hatice Ayan
EP1363 Presence of Occipital Neuralgia Predicts High Cervical Spinal Cord Lesion in Multiple Sclerosis Narayan R. Kissoon
EP1364 Cognition is not cognition: different aspects of cognitive deficits in MS patients Eva Kannamueller
EP1365 Prognostic assessment of cognitive impairment, fatigue development and depression according to brain lesions in patients with multiple sclerosis Olena Mialovytska
EP1366 Cognitive dysfunction in a Spanish cohort with Multiple Sclerosis: evaluation of cognitive reserve and other predictive factors Nuria Cerdá Fuertes
EP1367 Validation and cross-cultural adaptation of the Composite Autonomic Symptom Score-31 (COMPASS-31) in Croatian and Serbian multiple sclerosis patients Jelena Drulovic
EP1368 Are inhibitory and excitatory neurotransmitter levels in the posterior cingulate cortex associated with MS fatigue? Karen A. Ribbons
EP1369 Correlation of Fatigue with Cognitive and Physical Disability using Clinical Outcomes and MRI Measurements Salem Hannoun
EP1370 Sleep disorders in patients with Multiple Sclerosis and their link with fatigue Irene Gómez-Estévez
EP1371 Patient-reported outcomes are worse for progressive-onset MS than relapse-onset MS, particularly early in the disease process Yan Zhang
EP1372 Perceived cognitive impairment and cognitive test performance assessment in multiple sclerosis patients Rocco Totaro
EP1373 Continuous Facial Myokymia and Hemifacial Spasm at initial presentation of Multiple Sclerosis Oliver Cousins
EP1374 Symptoms of bowel dysfunction in people with muliple sclerosis Kirsteen Goodman
EP1375 The role of fatigue and cognitive impairment in early retirement due to multiple sclerosis Tommi Heinonen
EP1376 Symptoms related to Multiple Sclerosis: experience based on the systematic data collection from an electronic device René Robles Cedeño
EP1377 Analysis of Pre-Randomization Run-in Data Demonstrates Muscle Cramps and Spasms are Common, and Associated with Pain in MS Glenn Short
EP1378 Cognitive dysfunction and pseudobulbar affect comorbidity in MS Gabriel Pardo
EP1379 Early life residence in Gulf is associated with rapid multiple sclerosis progression in young Egyptians Hatem Samir Shehata
EP1380 Clinic Model for Intrathecal Baclofen Therapy in Patients with Multiple Sclerosis: A Retrospective Review Amy S. Thiessen
EP1381 Cognition, depression and clinical disease activity in the course of MS: a 4 year follow up Stephan Gierer
EP1382 The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations Cristina Valencia-Sanchez
EP1383 Multiple Sclerosis and Cognition: The Impact of Psychotropic Medications Daniel Golan
EP1384 The Comparison of Core Stability and Trunk Position Sense in Patients with Multiple Sclerosis and Healthy Controls Ceyla Irkec
EP1386 Emotional status in relapsing remitting MS patients Domenico Passafiume
EP1387 Effects of anxiety on motor imagery abilities in persons with multiple sclerosis Turhan Kahraman
EP1388 Evaluation of sleep quality and risk assessment of obstructive sleep apnea among MS patients Navid Manouchehri
EP1389 Preliminary Fatigue Subtype Discovery from the MS Mosaic Study Katherine Heller
EP1390 Epilepsy in multiple sclerosis (MS): clinical, electroencephalographic (EEG) and magnetic resonance imaging (MRI) characteristics Liudmila Averianova
EP1391 Patient-based outcome measures of the impact of disease in patients with multiple sclerosis and vitamin D deficiency Elena Oana Terecoasă
EP1393 Critical flicker frequency is reduced in multiple sclerosis patients independently of retinal axonal damage Noah Ayadi
EP1394 Long-term predictors of disability worsening in patients with multiple sclerosis in the phase 3 TRANSFORMS study Pavle Repovic
EP1395 Modified Brief International Cognitive Assessment for Multiple Sclerosis (mBICAMS): Towards validating the first Arabic version Hala Darwish
EP1396 Body worn sensors accurately and reproducibly quantify disability and walking impairment in a clinical setting in people with MS William Hodgkinson
EP1397 Can MS Patients Accurately Self-Time the 25-Foot Walk? Jaime L. Freiburger
EP1398 The use of a mobile-phone-based E-diary for evaluation of patient-reported outcomes and adherence to treatment of patients with Multiple Sclerosis Daniel Golan
EP1399 QuantemTool - Automated Measurement of Lesion Load and Cerebral Volume from Magnetic Resonance Images in Multiple Sclerosis Rafael F. Simões
EP1400 Validation of a clinical risk score for long-term progression of MS Juliana Calvet Kallenbach Aurenção
EP1401 Novel Integrative Approach Combining Patient, Physician and Empirical Assessments for Diagnosing Secondary-Progressive Multiple Sclerosis Daniela Piani Meier
EP1402 Biological rhythms in MS patients with mood disorders: what impact on quality of life? Lorena Lorefice
EP1403 How do people with multiple sclerosis feel about MRI? Insa Schiffmann
EP1404 Clinical validity of EDSS and SDMT in the detection of MS disease activity Ana Silva
EP1405 Optimizing Standards of Approach in Multiple Sclerosis Result in Better Outcomes. A Brazilian Open Label Study on Quality of Care Fernando F.A. Figueira
EP1406 Histologic validation of rapid myelin detection using quantitative MRI Marcel Warntjes
EP1407 Health-related coping and social interaction in people with Multiple Sclerosis supported by a social network: a pilot study with a new methodological approach Luigi Lavorgna
EP1408 Reliable cross-sectional correlations between a visual rating brain atrophy scale and quantitative MRI volumetric measures in multiple sclerosis Carlos Guevara
EP1409 Association between perceived fatigue and balance measured by posturography in patients with Multiple Sclerosis Ceyla Irkec
EP1410 Effect of physical activity level on functional exercise capacity in patients with multiple sclerosis Ceyla Irkec
EP1411 A longitudinal study correlating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls Jessica Frau
EP1412 Brief International Cognitive Assessment for Multiple Sclerosis and Corpus Callosum Atrophy Index: the Correlation between Quick and Easy-to-useTools in MS Patients Marco Aurelio de Caneda
EP1414 Treatment optImization using a Multidimensional dEcision model (TIME study): A proof-of concept study to assess a multidimensional standardized documentation model to optimize management of patients with multiple sclerosis in Germany Martin Stangel
EP1415 Epicardial fat tissue in patients with multiple sclerosis Meral Seferoğlu, Barış Şensoy, Demet Yıldız, Nilüfer Büyükkoyuncu Pekel Meral Seferoğlu
EP1416 An improved assay for therapeutic dose monitoring of natalizumab Bradley Messmer
EP1417 Evaluation of the Human Activity Profile on patients with multiple sclerosis Lina Savsek
EP1418 Do color vision testing and OCT parameters reflect the subclinical optic nerve involvement in Multiple Sclerosis? Burcu Yuksel
EP1420 Disability and unemployment utilization in patients with multiple sclerosis Brian Wong
EP1421 Satisfaction Analysis of Nursing Care Delivered to Patients with Multiple Sclerosis Using Virtual Technology in British Columbia, Canada Galina Vorobeychik
EP1422 Multiple Sclerosis Treatment Decisions: EDSS Independent Disease Impact/Reserve and the Use of Additional Economically Impactful Milestones that Matter Mark Gudesblatt
EP1423 Dutch trial-based economic evaluation of an intensive social-cognitive treatment (Can Do Treatment) in patients with relapsing remitting multiple sclerosis and low disability Peter J. Jongen
EP1424 Health Needs, Utilization, and Cost Coverage in MS: a NARCOMS, NMSS, iConquerMS Survey Deborah Miller
EP1425 Relapse Resolution and HCRU in Patients with Multiple Sclerosis: A Retrospective Study of Relapse Therapy Alternatives to Corticosteroids Tara Nazareth
EP1426 Access Barriers to disease-modifying therapies in Latin America: the impact of who makes treatment decisions, and when and why this is done Adriana J. Carra
EP1427 Activities of daily living, work productivity, and reliance on caregiver in patients with primary progressive multiple sclerosis Ning Wu
EP1428 Cost analysis of a relapse-free patient in relapsing-remitting multiple sclerosis Lucía Romero-Pinel
EP1429 Is retinal oximetry useful in diagnosis of neuromyelitis optica Devic? Tereza Svrčinová
EP1430 Vogt-Koyanagi-Harada disease is an important differential diagnosis for autoimmune acute visual impairment Yara Dadalti Fragoso
EP1431 North American Susac Syndrome Collaboration Classification Criteria: Labels for a Broader Spectrum of Susac Syndrome Gillian R. Paton
EP1432 Long-term outcomes in MOG-IgG+ Optic Neuritis Bruna K. da Costa
EP1433 The use of visual evoked potentials to differentiate optic neuropathies Mafalda Seabra
EP1434 Mood disorders and multiple sclerosis: a study based upon the French national health insurance databases Alice Guilleux
EP1435 Frequency of sleep abnormalities in a Brazilian cohort of patients with Neuromyelitis Optica Spectrum Disorder Marília M.M. Perin
EP1436 Assessing the risk of cervical dysplasia in women with MS compared to women without disease using a data linkage approach Emma Foster
EP1437 A prospective study of fracture risk, fall risk and serum vitamin D levels in ambulatory patients with moderately advanced multiple sclerosis Siew Mei Yap
EP1438 Multiple sclerosis and the risk of venous thrombosis: a systematic review Omnya Ahmed
EP1439 Low bone mineral density in neuromyelitis optica spectrum disorder : correlation with disease severity and body mass index Hye-Jin Cho
EP1440 Reverse takotsubo in a severe case of neuromyelitis optica Pauline Prin
EP1441 Bone health in neuromyelitis optica spectrum disorder: association with disability, steroid treatment, or leisure time exercise? Sun Young Im
EP1442 A Pilot Study Evaluating Changes in Clinical Outcomes with Weight Loss in People with Multiple Sclerosis Samantha Roman
EP1443 The link between dysautonomia and depression in multiple sclerosis Luka Crnošija
EP1444 Tobacco, alcohol, drug use and comorbidity issues in multiple sclerosis (MS): a pilot study Egle Sukockiene
EP1445 Concomitant changes in weight and in sleep quality among people with multiple sclerosis Kathryn C. Fitzgerald
EP1446 Headache characteristics in multiple sclerosis Yesim Beckmann
EP1447 Occurrence of cardiovascular (CV) risk factors and metabolic syndrome (MetS) in multiple sclerosis (MS) Kleoniki Maria Charisiou
EP1448 Effects of systolic blood pressure on brain integrity in multiple sclerosis Mauricio F. Farez
EP1449 Insulin resistance and multiple sclerosis: a pilot study in drug naive patients Smiljana Kostic
EP1450 Interaction between Comorbidities and Use of Disease Modifying Treatment in Impact on Quality of Life in a Regional Multiple Sclerosis Registry Tamela Stuchiner
EP1451 Risk of Developing Cancer and Its Impact on Patients with Multiple Sclerosis under Treatment with Immunomodulators Maria C. Curbelo
EP1452 Cognitive Profiles in Hong Kong Chinese with Relapsing and Progressive Multiple Sclerosis Alexander Y. Lau
EP1453 Interaction between Comorbidities and Use of Disease Modifying Treatment in Impact on Disability Status in a Regional Multiple Sclerosis Registry Lindsay Lucas
EP1454 Characterization of TSPO expression by conventional and mutliplex immunohistochemistry in marmoset EAE Irene N. Falk
EP1455 Markers of intestinal permeability defects are related to clinical activity in early multiple sclerosis Nieves Tellez
EP1456 Anti-AQP4 autoantibody, C5a, neutrophils and glutamate - four necessary, related components essential for neuromyelitis optica inflammation Pawel Piatek
EP1457 Influence of CBD in mesenchymal stem cells therapy in adoptively transferred experimental autoimmune encephalomyelitis. An in vivo and in vitro study Ruth García-Hernández
EP1458 Increased Post-Translational Lysine Acetylation of Myelin Basic Protein is Associated with Peak Neurological Disability in a Mouse Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Tina Khorshid Ahmad
EP1459 Oleanolic acid protects against intestinal permeability defects and its causes in experimental autoimmune encephalomyelitis Mª Luisa Nieto
EP1460 Is DPP4/GLP-1 pathway a possible target for remyelination? – A first cerebellum-focused approach using the cuprizone mouse model Filipe Palavra
EP1461 NMO IgG and AQP4 peptide can induce aggravation of EAMG and immune mediated muscle weakness Livnat Brill
EP1462 Innate immune activation is at the root of NMO-like lesion development Sven Olaf Rohr
EP1463 Gender features of hyperprolactinemia as a protective factor in animal models of multiple sclerosis Arkadi Predtetchinski
EP1464 Antinociceptive effects of a chronic fingolimod treatment in an optimized recurrent-remittent experimental autoimmune encephalomyelitis mouse model of multiple sclerosis-neuropathic pain Amélie Demosthenes
EP1465 Autoimmune and toxic demyelination is affected by HSP70 overexpression in oligodendrocytes and astrocytes Anna Jurewicz
EP1466 Inhibition of bone morphogenetic protein signaling with small molecules as a therapeutic approach in experimental autoimmune encephalomyelitis Herena Eixarch
EP1467 Functional regulation of abcg2 by apolipoprotein E in context of immunotherapies for multiple sclerosis Lisa Schrewe
EP1468 A new evaluation strategy to measure remyelination in the cuprizone model Uta Chrzanowski
EP1469 In vivo evolution by brain Magnetic Resonance Imaging of Interleukin 1 induced cortical demyelinating lesions in adult rats Berenice Anabel Silva
EP1470 Dimethyl fumarate changes the methylation pattern in CD4+ cells of MS patients Karen A. Ribbons
EP1471 Occurrence of allele T of glypican 5 polymorphism is associated with sex and age at onset in multilple sclerosis patients Agata Zajkowska
EP1473 Single nucleotide polymorphism in vitamin D hydroxylase gene is associated with susceptibility to Multiple Sclerosis in Slovaks Daniel Cierny
EP1475 Cell-specific transcriptional modulation induced by fingolimod treatment in Relapsing Remitting Multiple Sclerosis patients Laura Ferrè
EP1476 Familial involvement in multiple sclerosis Murat Terzi
EP1477 Role of CYP2R1 rs10766197 in MS risk and disease progression Giuseppe Salemi
EP1478 Association between DRB1*15:01 allele and five distinct Single Nucleotide Polymorphisms in the Brazilian familial form of Multiple Sclerosis Claudia Cristina Ferreira Vasconcelos
EP1479 Modulation of the Treg: Th17 axis in relapsing remitting multiple sclerosis after dimethyl fumarate therapy Nuala McNicholas
EP1480 IL-24 is produced both locally and peripherally by activated immune cells of MS patients Bieke Broux
EP1481 Melanocortin Receptor Mediated Anti-inflammatory Effect of Repository Corticotropin Injection on Human Monocyte-derived Macrophages Luke M. Healy
EP1482 Differential gene expression of SMAD family members and S1PR1 in circulating CD4+ T cells in multiple sclerosis Jose Manuel Garcia Dominguez
EP1483 Evaluation of Neutrophil Lymphocyte Ratio in Multiple Sclerosis Azize Esra Gürsoy
EP1484 Multiple Arboviral Infections and the Risk of Development of Neurological Complications Douglas Kazutoshi Sato
EP1485 Effect of serum of patients with optic neuromyelitis on the differentiation of neural stem cells. Preliminar study Vanesa Pytel
EP1486 Cell mechanical phenotyping of peripheral blood leukocytes in multiple sclerosis patients Katja Thomas
EP1487 Predictive biomarkers for optimal therapeutic response to fingolimod treatment in Multiple Sclerosis patients Silvia Presas
EP1488 Cerebrospinal fluid B-cell phenotype and intrathecal IgG synthesis suggest a local on-going follicular reaction in Multiple Sclerosis at clinical onset Francesca Grassivaro
EP1489 Disturbance of human brain endothelial barrier function via chemokine receptor CXCR2 Axel Haarmann
EP1490 Fractalkine (CX3CL1) in the sera of patients with Multiple Sclerosis and Neuro- Behcet’s Disease Ceyla Irkec
EP1491 25 Hydroxyvitamin D and Cytokines in bulgarian patients with multiple sclerosis Georgi S. Slavov
EP1492 Vascular inflammation markers in multiple sclerosis: possible role in oligoclonal band formation Recai Türkoğlu
EP1493 Neuromyelitis optica spectrum disorders with Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein antibodies in Turkish Population:A Comparative Study Egemen İdiman
EP1494 Carotid intima-media thickness is associated with HLA-DRB1*15 in multiple sclerosis Agustín Oterino
EP1495 Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study Simona Rolla
EP1496 Does Vitamin D facilitate a chronic inflammatory response in Multiple Sclerosis Ming Lu
EP1497 Osteopontin plasma levels in relapsing remitting multiple sclerosis Sepideh Allahdadian
EP1498 Immunity in NeuroBehcet disease Mariem Kchaou
EP1499 HLA-DRB1*15:01 confers susceptibility to Epstein-Barr Virus infection to B cells linking genetic and environmental risk factors for multiple scleros Klemens Ruprecht
EP1500 Herpes Virus and Varicella Zoster Virus antibodies Index in the cerebrospinal fluid of patients with multiple Sclerosis patients and Clinically Isolated Syndrome Maria-Eleftheria Evangelopoulos
EP1501 Dietary intakes of minerals and disability in multiple sclerosis; is there any association? Mohammad Bagher Maljaei
EP1502 Clinical relevance of Vitamin D and Cholesterol serum levels in Multiple Sclerosis: A real-word data study Josefa Pérez-Lucas
EP1503 Fats and Multiple Sclerosis; Association between fats/oils intake and disability in patients with MS Mohammad Bagher Maljaei
EP1504 Vitamin D level and quality of life in patients with multiple sclerosis Yesim Beckmann
EP1505 Moving from systemic to central nervous system inflammation: the role of A20 in the neuropathology of Multiple Sclerosis Simona Perga
EP1506 The unglycosylated KIR4.1 extracellular domain constitutes an autoimmune target in Multiple Sclerosis and can promote demyelinating encephalomyelitis in mice Arnaud B. Nicot
EP1507 Tart cherry extract as a powerful substance to ameliorate oxidative stress in the cuprizone model Newshan Behrangi
EP1508 The Effect of Simvastatin on Autophagy in Mammalian Cells Eleanor James
EP1509 Axonal damage and motor impairment correlate with glial cell senescence in a model of multiple sclerosis Dimitrios Papadopoulos
EP1510 Brain volume loss in neuromyelitis optica spectrum disorder Jimena Miguez
EP1511 Increased glutamate is the dominant cause of deep brain atrophy and multiple sclerosis severity Ema Kantorová
EP1512 Factors that regulate endogenous expression of the myelinating protein Gas6 in the brain Sassan Hafizi
EP1513 In vivo validation of chemical compounds with remyelinating potential Carme Costa
EP1514 Classifying Multiple Sclerosis Lesions with T1-Weighted MR and Myelin Imaging Caroline Köhler
EP1515 Optimal timing of gadolinium-enhanced 3D FLAIR MRI for detection of leptomeningeal enhancement in multiple sclerosis David S. Titelbaum
EP1516 Supervised detection of newly appearing T2-w multiple sclerosis lesions with subtraction and deformation fields features Xavier Llado
EP1517 Spinal cord pathology and MS phenotypes – lesions, diffusion changes and spinal cord atrophy in 1036 multiple sclerosis patients Manuela Vaneckova
EP1518 Periventricular lesions and 2016 MAGNIMS criteria for dissemination in space in patients with clinically isolated syndromes María Díaz Sánchez
EP1519 Iron deposition and volumes determination of subcortical, cerebellar and brain stem deep gray matter in multiple sclerosis: correlations Belgin Kocer
EP1520 Normative data of MRI-derived hippocampal volume from a large dataset of healthy subjects Ludovico Luchetti
EP1521 Accelerated myelin water imaging for assessment of cervical spinal cord demyelination in multiple sclerosis and neuromyelitis optica spectrum disorder Adam Dvorak
EP1522 Demographic analysis and lesion characterization of leptomeningeal enhancement in multiple sclerosis Renate Engisch
EP1523 Regional distribution of cortical and subcortical damage in CIS patients: A study of first-year changes with clinical, CSF and radiological correlations Rumaiza Alyafeai
EP1524 Does frequent MRI scanning improve accuracy of evaluation of brain atrophy in individual multiple sclerosis patients? Tomas Uher
EP1525 Comparison of methods for brain atrophy assessment in multiple sclerosis Loredana Storelli
EP1526 The cytoarchitectonic anterior-posterior subdivision of BA4 reveals different resting state networks suggestive of maladaptive mechanisms in MS Adnan A.S. Alahmadi
EP1527 Lower arterial cross-sectional area of carotid and vertebral arteries and higher frequency of secondary neck vessels are associated with multiple sclerosis Dejan Jakimovski
EP1528 Correlation between cognitive dysfunction and the corpus callosum index, brain atrophy, lesion load in multiple sclerosis Lucas Immich Gonçalves
EP1529 Pathophysiology of MS tremor: an fMRI study Frederique Maria Christina Boonstra
EP1530 Quantum – Value and feasibility of standardised, quantitative MRI analyses of MS patients in routine clinical practice Sven Schippling
EP1531 Accuracy and reliability of manual versus automated thalamus segmentation in patients with MS Ann-Christin Ostwaldt
EP1532 Impact of 3 Tesla MRI on Lesion Detection in Clinically Isolated Syndrome: A MAGNIMS Multicentre Study Marloes H.J. Hagens
EP1533 Comparison of MRI findings in progressive multifocal leucoencephalopathy among HIV-positive patients and patients treated by immunosuppressive drugs, Natalizumab or Rituximab Manel Alleg
EP1534 Retinal Vessel Oxygen Saturation in Multiple Sclerosis Helle H. Nielsen
EP1535 Stratifying FLAIR-hyperintense white matter lesions in a pilot study of MS, CIS, dementia, and concussion using magnetic susceptibility mapping Vanessa Wiggermann
EP1536 Myelin and total water content show similar distributions in neuromyelitis optica and multiple sclerosis lesions Irene M. Vavasour
EP1537 The corticospinal tract in relapsing-remitting multiple sclerosis: a pilot tractography and fixel-based MRI analysis at ultra high-field Myrte Strik
EP1538 MRI-based Measures for Quantifying Treatment Efficacy in Multiple Sclerosis Kristin A. Linn
EP1539 Time resolved MR angiography in patients with multiple sclerosis, their healthy siblings and unrelated controls Enedino Hernández-Torres
EP1540 Functional brain network stability in natalizumab treated multiple sclerosis patients: a one year follow-up study Kim A. Meijer
EP1541 Resting State in relapsing-remitting MS patients with verbal episodic memory or social cognition impairment and low level of motor disability Ethel Ciampi
EP1542 A deep-learning method for tissue volumetry from multi-spectral magnetic resonance imaging in multiple sclerosis Richard McKinley
EP1543 3T-PET/MRI discloses different metabolic states of cortical lesions in Multiple Sclerosis Davide Poggiali
EP1544 Neuropsychological correlations differ according to the spatial distribution of corpus callosum atrophy in multiple sclerosis Bruna K. da Costa
EP1545 Comparison of automated brain atrophy and lesion volume quantification tools in multiple sclerosis patients Julia Albright
EP1546 A comparison of spinal cord grey and white matter atrophy in MS and healthy controls with clinical correlations Jaume Sastre-Garriga
EP1547 Magnetic Resonance Imaging in the NMO Seropositive and seronegative for AQP4 Nadja Emídio Araújo
EP1548 MRI in Transverse Myelitis: correlation with expanded disability status scale Kateryna Schwartz
EP1549 Resting state functional networks and cognitive performance in clinically isolated syndromes Marta Batlle
EP1550 Information processing and brain flexibility in multiple sclerosis: the relevance of state-contrast Quinten van Geest
EP1551 Longitudinal Variation in Structural and Diffusion Parameters of Fatigue Patients in Multiple Sclerosis Sara Razmjou
EP1552 Magnetic resonance fingerprinting indicates thalamic atrophy in multiple sclerosis and reflects extrinsic pathology Daniel Ontaneda
EP1553 Intracranial Volume as a Surrogate for Maximal Lifetime Brain Growth in Adult-Onset Multiple Sclerosis: Comparison with Healthy Controls Jiwon Oh
EP1554 Verbal memory and brain micro-structural changes in Multiple Sclerosis Shmuel Miron
EP1555 OFSEP MRI protocol: the need of good practice’s standardization from clinicians to scientists François Cotton
EP1556 [18F]-Florbetaben-PET/MRI as myelin-specific molecular imaging: a pilot study in patients with different white matter diseases Sarah Haars
EP1557 Basal ganglia volume and cognitive function in newly diagnosed and untreated multiple sclerosis patients Ørjan Bergmann
EP1558 Clinicoradiological correlation revisited in Relapsing onset North African Multiple Sclerosis Mohammad Hamed
EP1559 New and enlarging lesion location for different MS clinical phenotypes Wim Van Hecke
EP1560 Can MR Permeability and Contast Enhanced (CE)-FLAIR demonstrate AQP4 Channel Dysfunction in NMOSD Patients? : Work in Progress Serhat Vahip Okar
EP1561 Racial and environmental influences on North African multiple sclerosis, application of global and regional brain atrophy measures Mohammad Aboulwafa
EP1562 OCT in familial and sporadic MS patients: correlation between RFNL and macular volume Malgorzata Siger
EP1563 Evaluation of the neurodegeneration processes in dynamics in multiple sclerosis Denis S. Korobko
EP1564 Retinal Optical Coherence Tomography in Chronic Relapsing Inflammatory Optic Neuropathy: a retrospective analysis of distinctive features Maziar Eslami Farsani
EP1565 Neurophysiological correlates of anxiety and depression symptoms in patients with multiple sclerosis: A transcranial magnetic stimulation study Samar S. Ayache
EP1566 Cortical excitability and alexithymia in multiple sclerosis: A transcranial magnetic stimulation study Moussa A. Chalah
EP1567 Cerebral Vascular Reactivity in Multiple Sclerosis G. Tekgol Uzuner
EP1568 Electrophysiological study of cognitive function through working memory in patients with multiple sclerosis Alejandra Figueroa
EP1569 Correlation between Visual Evoked Potentials and Cognitive Impairment in Multiple Sclerosis Patients Nuray Bilge
EP1570 Visual evoked potentials with low-contrast stimuli in the evaluation of optic neuritis Joong-Yang Cho
EP1571 Validation of the french version of the bicams and comparison with the macfims Mathilde Deloire
EP1572 Association between cytokine gene polymorphisms and cognitive functions in relapsing-remitting multiple sclerosis Georgi S. Slavov
EP1573 The executive component of naming ability in Multiple Sclerosis Héloise Joly
EP1574 Cognitive profiles in multiple sclerosis: beyond information processing speed Vanesa Pytel
EP1575 The relationship between attention impairment and information processing speed in patients with multiple sclerosis Karin Zebenholzer
EP1576 Adaptive coping interventions should be a priority for people with multiple sclerosis and cognitive impairment Lisa B. Grech
EP1577 Interpretability of the Patient-Reported Multiple Sclerosis Neuropsychological Screening Questionnaire: a cognitive screening tool? Ilse M. Nauta
EP1578 Cognitive-Motor interaction in patients with multiple sclerosis María Bárbara Eizaguirre
EP1579 Functional MRI of the symbol digit modalities task in relapsing remitting multiple sclerosis Matthias Grothe
EP1580 Cognitive impairment in neuromyelitis optica and multiple sclerosis Eva Fernández Díaz
EP1581 Executive functioning and delayed verbal memory retrieval in patients with multiple sclerosis Fabiola García-Vaz
EP1582 Cognition and the cerebellum in multiple sclerosis (MS) Jonathan C. Hinchliffe
EP1583 Resilience Matters in Multiple Sclerosis: The Independent Contribution of Psychological Resilience to Disability Sylvia Klineova
EP1584 The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Portuguese population with Multiple sclerosis Claudia Sofia Sousa
EP1585 Visual Perceptual Organization Ability in Multiple Sclerosis Serpil Demirci
EP1586 Neuropsychological Management of Multiple Sclerosis: Evaluation of the added value of a supervised and customized cognitive rehabilitation program for self-used at home Gilles Defer
EP1587 Cortical lesions correlate with cortical atrophy and drive cognitive impairment in multiple sclerosis Todor Kunchev
EP1588 Subjective versus objective cognitive screening of patients with multiple sclerosis Lucie Kadrnozkova
EP1589 A Cognitive Occupation-Based Programme for People with Multiple Sclerosis (COB-MS): A study to test feasibility and clinical outcomes Sinead M. Hynes
EP1590 Cognitive disorders in multiple sclerosis: a screening tool proposed in current practice. The experience of the Rhône-Alpes SEP Network Laurent Guilloton
EP1591 No evidence of disease activity and cognition in relapsing-remitting multiple sclerosis Ricardo Alonso
EP1592 Characteristics of verbal strategies used in semantic and phonemic fluency in patients with multiple sclerosis Ernest Tyburski
EP1593 Adiponectin as a possible biomarker in Multiple Sclerosis Elisabetta Signoriello
EP1594 Cerebrospinal fluid oligoclonal IgM bands and prognosis in Multiple Sclerosis patients: pooled long-term follow-up data Diana Ferraro
EP1595 CSF neurofilament light chain provides a valuable prognostic tool in Multiple Sclerosis Maria João Leitao
EP1596 Principal Component Analysis of Intrathecal Chemokine Expression in Multiple Sclerosis and other neurological diseases Francesca Gilli
EP1597 Lactate, beta2-microglobulin and ACE in cerebrospinal fluid as markers of clinical disease course and severity in patients with multiple sclerosis Axel Haarmann
EP1598 Cerebrospinal fluid levels of neurofilament light chain, C-X-C ligand motif 13, and chitinase-3-like protein 1 reflect distinct pathological processes in multiple sclerosis Mattia Zanoni
EP1599 CSF cell signature and biomarkers of neuroinflammation and neurodegeneration in MS: preliminary results of the OBOE study Anne H. Cross
EP1600 Neuronal and glial CSF biomarkers in patients with Secondary Progressive Multiple Sclerosis treated with dimethyl fumarate Keith R. Edwards
EP1601 Translational multi-omics identifies four peptides differentially regulated in the CSF of relapsing and progressive MS Zsolt Illes
EP1602 Disease Modifying Therapies Alter MicroRNA Expression Patterns in Distinct Immune Cell Subsets in Relapsing-Remitting Multiple Sclerosis Dylan A. Galloway
EP1603 Autoantibodies in neuromyelitis optica spectrum disorder and clinical characteristics Eun-Jae Lee
EP1604 The role of metabolomics in Multiple Sclerosis sub-classification and clinical course Petros Alatzas
EP1605 NFL and CXCL13 reveal disease activity in clinically and neuro-radiologically stable MS Lenka Novakova
EP1607 A comprehensive in silico analysis of transcripts upregulated in multiple scleroses patients and ZIkV infection: identification of similar pathways Fabrícia Fontes-Dantas
EP1608 CSF interleukin 6 concentrations in pseudotumoral inflammatory CNS lesions suspicious of CNS lymphoma Aurelian Ungureanu
EP1609 Ozanimod (RPC1063) reduces the plasma biomarker neurofilament light chain in preclinical rodent models of multiple sclerosis Kristen R. Taylor Meadows
EP1610 JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients Pabitra Basnyat
EP1611 Comparing the CSF proteome of neuromyelitis optica patients with and without anti-AQP4 antibodies – preliminary data Yu Yi M. Wong
EP1612 OFSEP biobank: high quality samples for powerful research on MS biomarkers Nathalie Dufay
EP1613 Serum Neurofilament light chain as a predictor of long-term outcomes in patients with CIS in the BENEFIT 11 trial Jens Kuhle
EP1614 mTOR signaling plays a crucial role in IFN-β non-responsiveness in MS patients with high serum Sema4A levels Akiko Hosokawa Namba
EP1615 Intrathecal IgM synthesis is associated with conversion of CIS patients to definite MS André Huss
EP1616 Determination of the altered metabolome as an expected biomarker of active plaques in relapsing- remitting multiple sclerosis patients Natalia Niedziela
EP1617 Towards personalized dosing of natalizumab in multiple sclerosis: an ongoing multicentre trial in the Netherlands Zoé L.E. van Kempen
EP1618 Two-year follow-up of 19 patients treated with alemtuzumab for active relapsing-remitting MS: the Lyon’s experience Françoise Durand-Dubief
EP1619 Impact of dimethyl fumarate (DMF) treatment on immune tolerance during Multiple Sclerosis Giorgia Teresa Maniscalco
EP1620 Inhibition of mitochondrial respiration with teriflunomide modulates antigen-specific immune responses in an affinity-dependent fashion Melanie Eschborn
EP1621 Should lesions enhanced by gadolinium injection predict efficiency of first line therapies ? Pierre Labauge
EP1622 Comparative efficacy of Teriflunomide versus Dimethyl-Fumarate: a French multicenter observational study from the french national OFSEP cohort David Laplaud
EP1623 Real clinical experience in multiple sclerosis patients treated with Alemtuzumab in the northwest of Spain Ana Maria Lopez Real
EP1624 Comparison of the B-Cell Recovery Time Following Discontinuation of Anti-CD20 Therapies David Leppert
EP1625 Lymphocyte recovery in real life clinical practice after discontinuation of fingolimod in patients with multiple sclerosis Sara Nagy
EP1626 Real world effectiveness and safety of alemtuzumab in MS patients Sara Eichau
EP1627 Baseline characteristics and safety profile of patients in the first interim analysis of the peginterferon beta-1a Phase IV POP Study Maria L. Naylor
EP1628 Halting disability progression in multiple sclerosis with immunomodulatory injectable treatments: is it achievable? Yara Dadalti Fragoso
EP1629 Effectiveness of fingolimod in Spanish patients with Relapsing-Remitting Multiple Sclerosis in the clinical practice Virginia Meca-Lallana
EP1630 Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-world EFFECT Study Jacob Sloane
EP1631 Delayed-release dimethyl fumarate significantly reduced relapse based outcomes vs. interferon, glatiramer acetate, or teriflunomide: pairwise propensity-matched comparative effectiveness analyses of the German NeuroTransData registry Stefan Braune
EP1632 Comparison of Natalizumab vs Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience Brandi L. Vollmer
EP1633 Teriflunomide inhibits activation and proliferation of B-cells in patients with relapsing remitting multiple sclerosis (RRMS) Silva Markovic-Plese
EP1634 Laquinimod protects optic nerve and retina in an experimental autoimmune encephalomyelitis model Stephanie C. Joachim
EP1635 Acceptability of first-line Disease-Modifying Drugs in Relapsing-RemittingMultiple Sclerosis: a real-life multicenter study Diana Ferraro
EP1636 Characterizing temporal pattern of Alemtuzumab infusion-associated reactions: experience in clinical practice in a multicentre study of the northwest of Spain Ana Maria Lopez Real
EP1637 Effectiveness of fingolimod in Spanish patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in daily clinical practice: Fingoview study multivariate analysis Sergio Martínez Yélamos
EP1638 Tocopherol-Based Emulsions as Functional Vehicles for Antigen-Specific Immunotherapy Ameliorate Experimental Autoimmune Encephalomyelitis in vivo J. Daniel Griffin
EP1639 Acute Tumefactive Demyelination in a patient on Rituximab; a case report Burhan Chaudhry
EP1640 Effectiveness and safety of fingolimod in Spanish Relapsing-Remitting Multiple Sclerosis patients in clinical practice (Fingoview study): Subanalysis of patients previously treated with first line injectable disease-modifying treatment Javier Mallada
EP1641 Unexpected systemic reactions following glatiramer acetate 40 mg injections. Experience at 2 Multiple Sclerosis Centers Chiara Zecca
EP1642 Real life efficacy and safety of Fingolimod : a french SouthWest and Center cohort Alexandra Roux
EP1643 The efficacy and safety of the biosimilar interferon beta-1a Teberif® in patients with relapsing-remitting multiple sclerosis: data from a comparative international multicenter double-blind placebo-controlled randomized Phase III study Camila Tursunova
EP1644 Real world data on teriflunomide and dimethyl fumarate treatment of multiple sclerosis Hilde Norborg
EP1645 Comparing efficacy between natalizumab and fingolimod: radiological findings from BEST-MS study Mikael Cohen
EP1646 A novel case of autoimmune myositis after alemtuzumab therapy for multiple sclerosis Patrick Aouad
EP1647 The Alemtuzumab MS Safety Systems (AMS3) study: clinical outcomes Stephen Reddel
EP1648 Observational study of the factors leading to the switch to fingolimod after first-line therapy in patients with relapsing-remitting multiple sclerosis in France: Interim analysis ESGILE Study Ayman Tourbah
EP1649 Efficacy and Safety of Daclizumab Beta in Patients with Relapsing-Remitting MS Switching from Natalizumab: Rationale and Study Design of the Phase 3b SUSTAIN Study Gavin Giovannoni
EP1650 Real-World Treatment Satisfaction With Teriflunomide: Results From the European Cohort of the Phase 4 Teri-PRO Study Patrick Vermersch
EP1651 Surface Charge distribution, an attribute linked with immunogenicity of nanoparticles, is different for Follow-On Glatiramer Acetate products approved in EU, Russia, Latin America and USA compared with Copaxone Arthur Komlosh
EP1652 Physicochemical and Biological Characterization of the European Follow-On Glatiramer Acetate Product as Compared to Copaxone Bracha Timan
EP1653 A Prospective Evaluation of Fingolimod MRI outcomes in Puerto Rico Hispanic population Eduardo Estades
EP1654 Teriflunomide in Real World Practice: further benefit in previously treated multiple sclerosis patients. A multicenter, 2 years retrospective study Agustín Oterino
EP1655 Efficacy and safety of natalizumab extended interval dosing Bassem Yamout
EP1656 A case of Legionnaires’ disease in a patient on dimethyl fumarate therapy for relapsing-remitting multiple sclerosis Rachel Brandstadter
EP1657 Brain atrophy and disease free status over 3 years in multiple sclerosis patients under interferon beta 1a subcutaneous treatment Juan I. Rojas
EP1658 Characterising properties of dimethylfumarate on innate and adaptive immunity: longitudinal data from MS patients Martin Diebold
EP1659 RAM-589.555 induces B-cell apoptosis during acute multiple sclerosis relapse: In-vitro study Michael Gurevich
EP1660 Is brain atrophy of multiple sclerosis patients treated with Fingolimod different from those treated with interferon at high doses? Juan Luis Ruiz Peña
EP1661 Lymphocytes subsets after one year of dimethylfumarate treatment in multiple sclerosis: a real life study Sara La Gioia
EP1662 Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments Benedetta Forci
EP1663 Radiological and cognitive outcomes among patients randomized to interferon beta, glatiramer acetate or fingolimod in PREFERMS Samuel F. Hunter
EP1664 Profile of ms patiens treated with Alemtuzumab in real world Celia Oreja-Guevara
EP1665 Switching from fingolimod to alemtuzumab in patients with active relapsing multiple sclerosis Antonia Carroll
EP1666 Teriflunamide and dimethyl fumarate: results from clinical practice Carlota Cunha
EP1667 Multiple sclerosis Outcome Determination Evaluating Real Differences After TimE (MODERATE): Treatment variations and outcomes in Scotland Paul J. Gallagher
EP1668 Experience with Tocilizumab in treatment of Neuromyelitis Optica Virginia Meca-Lallana
EP1669 Safety and efficacy of dimethyl fumarate in a real-world relapsing-remitting multiple sclerosis population Ariana Barros
EP1670 Disease Modifying Therapy Use in Multiple Sclerosis Patients with Comorbidities Devon S. Conway
EP1671 Infusion-related reactions with ocrelizumab in phase III studies Jérôme de Seze
EP1672 Cyclophosphamide in the treatment of multiple sclerosis. Can the "elders" protect against neurodegeneration? Artemios Artemiadis
EP1673 Severe Acute Non-immune Thrombocytopenia during the first cycle of treatment with Alemtuzumab Ester Carreón Guarnizo
EP1674 Contribution of K+ channels and P2X7 receptor in 7-ketocholesterol – induced lipotoxicity on 158N murine oligodendrocytes: new pharmacological targets to prevent oligodendrocytes dysfunctions in multiple sclerosis Gérard Lizard
EP1675 The Australian Alfred Alemtuzumab Experience Cassie Nesbitt
EP1676 Attenuation of 7-ketocholesterol and 7β-hydroxycholesterol – induced lipotoxicity by dimethylfumarate, monomethylfumarate and biotin on 158N murine oligodendrocytes Gérard Lizard
EP1677 Modifying the migration velocity of oligodendrocyte progenitors by altering the expression of PDGFRα via CRISPR-Cas9 Maria J. Ulloa Navas
EP1678 Effect of erythropoietin on disease activity and conversion into multiple sclerosis after optic neuritis Kurt-Wolfram Sühs
EP1679 Mapping proteomics changes induced by Fingolimod in different regions of the brain and retina Vivek K. Gupta
EP1680 Observational Study to Evaluate Real-World Effectiveness in Multiple Sclerosis Patients Treated With Alemtuzumab in Germany: TREAT-MS Study Preliminary Results Katja Thomas
EP1681 A Retrospective Claims Analysis: Compliance and Discontinuation Rates Among Canadians MS Patients Treated with Disease-Modifying Therapies at 6, 12, and 24-Months - Canadian Real World Experience Pierre Duquette
EP1682 A Swedish Nationwide Pharmaco-Epidemiological Study of the Long-Term Safety and Effectiveness of Dimethyl Fumarate (IMSE 5) Linda Forsberg
EP1683 Clinical and Economic Evaluation of Alemtuzumab Compared to Ocrelizumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States: A Payer Perspective Viktor Chirikov
EP1684 Regression of erythroblastaemia in natalizumab-treated patients with multiple sclerosis after drug suspension Sara La Gioia
EP1685 Case series: A specialty center 10 year experience with use of azathioprine in neuromielytis optica spectrum disorders (NMOSD) Ana Beatriz A G R Gomes
EP1686 Real World Evidence (RWE) on Long-Term Persistence to Medications for Relapsing-Remitting Multiple Sclerosis (RRMS) in the Australian Community (REALITY) Mark Schulz
EP1687 Long-term real-life retrospective analysis on interferon β1-a use in RRMS patients in Finland Marja-Liisa Sumelahti
EP1688 The burden of treatment monitoring in disease modifying therapies in Europe and the United States Joanna White
EP1689 A Swedish Nationwide Pharmaco-Epidemiological Study of the Long-Term Safety and Effectiveness of Alemtuzumab (IMSE 3) Åsa Leandersson
EP1691 A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis Marcello Moccia
EP1692 Adherence, cognition and behavioral performance in relapsing-remitting MS (RRMS) patients using the electronic autoinjector RebiSmart: 1 and 2 year follow-up from the German multicenter RebiSmart study D. Rau
EP1693 Real-world changes in immunological and routine lab parameters of multiple sclerosis patients in 72 months long-term follow up Maxi Kaufmann
EP1694 Hands on experience in therapy management and challenges addressed in an individualized patient support program of three different therapeutic disease-modifying approaches to treat Multiple Sclerosis in Germany Yvonne Begus-Nahrmann
EP1695 Effectiveness and Safety of Long-Term Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease Galina Vorobeychik
EP1696 Interim data from the Hungarian fingolimod registry (CFTY720DHU01) Krisztina Bencsik
EP1697 Long-term safety profile of fingolimod in the treatment of multiple sclerosis: Results of the ‘DIAMOND’ non-interventional, prospective, observational study conducted in the routine care of Greece Dimos Dimitrios Mitsikostas
EP1698 Discontinuation of dimethyl fumarate in relapsing multiple sclerosis in a single centre Rachel J. Dorsey-Campbell
EP1699 Retrospective longitudinal analysis of cognition and clinical-behavioral parameters (PRO) in relapsing-remitting multiple sclerosis (RRMS) patients treated with Teriflunomide – results from a 12 month registry study in German practice centers Herbert Schreiber
EP1700 The inclusion of cognitive evaluation into NEDA-3 (NEDA-3/Co) further confirms the high efficacy of natalizumab in multiple sclerosis Lisa Federle
EP1701 Real-World Evidence of Patients Treated With Alemtuzumab in Canada Alden Smith
EP1702 Illness- and Medication-perceptions are key predictors of adherence in Patients with MS Anat Wolkovich
EP1703 The 20-Year History: Change of Multiple Sclerosis Patient Profile over 20 Years Serkan Ozakbas
EP1704 Safety and Efficacy of Long-Term Treatment With Daclizumab Beta: 6-Year Results From the SELECTED Extension Study Ralf Gold
EP1705 Real World lab data: Intra- and inter-individual changes in Fingolimod treated MS patients Maxi Kaufmann
EP1706 Analysis of the effectiveness of natalizumab through non-evidence of disease activity (NEDA-3) criteria in real world practice in a tertiary hospital in Asturias Spain Patricia Suárez-Santos
EP1707 Six year prospective immunological study of Alemtuzumab treated patients: identification of markers of the clinical response Luca Durelli
EP1708 Adherence to oral versus injectable disease-modifying therapies for multiple sclerosis using French national health insurance databases Jonathan Roux
EP1709 Long-term effectiveness of fingolimod in multiple sclerosis patients treated in the routine care of Greece: Results of the ‘DIAMOND’ non-interventional, prospective, observational study Dimos Dimitrios Mitsikostas
EP1710 Biomarkers for monitoring natalizumab treatment in multiple sclerosis Gerd Haga Bringeland
EP1711 Long-term experience with Natalizumab as first-line treatment for highly active pediatric multiple sclerosis: A case report Smail Daoudi
EP1712 Optimal response to dymethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile Silvia Medina
EP1713 Impact of Alemtuzumab on Work Capacity Based Upon Evidence From the CARE-MS II Study Jennifer D. Guo
EP1714 effectiveness of Alemtuzumab in RRMS patients with an EDSS score of ≤ 5 or >5 Rocío López Ruiz
EP1715 Long-term Disability Outcomes in Teriflunomide-Treated Patients in TEMSO and TOWER: An EDSS and FSS Categorical Analysis Fred Lublin
EP1716 Long-term efficacy, safety, tolerability and quality of life with fingolimod treatment in patients with multiple sclerosis in real-world settings in France: VIRGILE two-year results Christine Lebrun-Frenay
EP1717 3 year follow-up of 80 patients with RRMS: switching therapies between injectable therapies versus escalation to fingolimod Evangelos Kouremenos
EP1718 Persistent No Evidence of Disease Activity during Natalizumab Treatment Francesca Sangalli
EP1719 An investigation into the Relationship between the Multiple Sclerosis Impact Scale (MSIS-29) and Predicted Medication Adherence as measured by the Morisky Medication Adherence Scale (MMAS-8) Mark Gudesblatt
EP1720 TRUST – evaluation of baseline data to investigate an integrated approach for optimised patient management in multiple sclerosis patients treated with natalizumab Hans-Peter Hartung
EP1721 severe rebound tumefactive relapse in a MS patient on Lemtrada Sonia Kumari
EP1722 Secondary Antibody Deficiency and infection following B-cell depletion for CNS neuroinflammation Emma C. Tallantyre
EP1723 Progressive Multifocal Leucoencephalopathy in patient with Fingolimod Treatment: one-year follow-up Francesca Rossi
EP1724 Incidence of cervical dysplasia in females receiving Alemtuzumab: an australian single centre observational study Cassie Nesbitt
EP1725 Myocardial Ischemia associated with Alemtuzumab infusion in Multiple Sclerosis-a case report Valentina Camera
EP1726 Evaluation of the benefit of an initial risk-assessment and individualized patient coaching for adherence for three different-modifying therapies Yvonne Begus-Nahrmann
EP1727 The results of a controlled, prospective study of relapsing MS patients at risk for PML who switched from long term natalizumab to teriflunomide in a controlled, prospective study Keith R. Edwards
EP1728 Hepatic toxicity appears infrequently and early after initiation of Teriflunomide in real-world practice. A multicenter, 2 years follow-up retrospective study Roberto Suarez
EP1729 Mortality from Listeria monocytogenes Meningoencephalitis following escalation to Alemtuzumab Therapy for Relapsing-Remitting Multiple Sclerosis Luke J.W. Canham
EP1730 Clinical activity after Fingolimod cessation: disease reactivation or rebound? Jessica Frau
EP1731 Delayed lymphocyte re-population following discontinuation of Dimethyl Fumarate and after switching to other disease modifying drug therapies Bhupendra Khatri
EP1732 Teriflunomide (Aubagio®) International Pregnancy Registry: Enrolment Update Christine Lebrun-Frenay
EP1733 Unexpectedly high rate of discontinuation of pegylated interferon beta-1a among previously stable interferon-treated patients due to poor tolerability and disease recurrence Pavle Repovic
EP1734 Lack of clinically meaningful changes in cardiac effects from co-administration of ozanimod and a beta-blocker or a calcium channel blocker Jonathan Q. Tran
EP1735 Anti- JCV antibody Sero-positivity and index value among Iranian patients with multiple sclerosis and its correlation with demographic data and previous therapies Sogol Koolaji
EP1736 Pregnancy Outcomes with Delayed-release Dimethyl Fumarate: Interim Results from an International Registry Nicholas J. Everage
EP1737 Acalculous cholecystitis as an infusion-related reaction in alemtuzumab-treated RRMS patients. Long-term follow-up and conversion to chronic disease Steffen Pfeuffer
EP1738 Rituximab-induced interstitial lung disease in a patient with neuromyelitis optica spectrum disroder: The first case report So Hyun Ahn
EP1739 Progressive Multifocal Leukoencephalopathy during Teriflunomide in Multiple Sclerosis Patient: case report Lorena Lorefice
EP1740 Alemtuzumab-associated anti-glomerular basement membrane antibody-positive glomerulonephritis complicated by secondary thrombotic microangiopathy and posterior reversible encephalopathy syndrome Siew Mei Yap
EP1741 Suspected pneumocystis jirovecii pneumonia after alemtuzumab Elizabeth Daphne Verter
EP1742 Pharmacodynamics and pharmacokinetics of Natalizumab administered at Extended Interval Dosing Lana Zhovtis Ryerson
EP1743 Using lumbar puncture to exclude progressive multifocal leukoencephalopathy in people with multiple sclerosis on natalizumab: real life experience in a single centre Richard Nicholas
EP1744 Type 0 blood group associates with higher anti-JCV antibody levels Clemens Warnke
EP1745 Low signal intensity rim on magnetic susceptibility imaging in patients from the Dutch-Belgian natalizumab-associated PML cohort Martijn T. Wijburg
EP1746 Understanding the treatment preferences of people with relapsing remitting multiple sclerosis Helen Ford
EP1747 Behçet’s disease following alemtuzumab treatment for multiple sclerosis Sebastian Luppe
EP1748 Safety issues in multiple sclerosis patients treated with alemtuzumab in real world Celia Oreja-Guevara
EP1749 Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis Mario Habek
EP1750 Neurologists’ tolerance to risk and uncertainty in the practical management of multiple sclerosis Gustavo Saposnik
EP1751 Impact of a community pharmacy-based information protocol on multiple sclerosis patients’ adherence to treatment with dimethyl fumarate: TECPHIE, a randomized study vs usual practice Yves Michiels
EP1752 Listeria monocytogenes meningitis after course of alemtuzumab for relapsing-remitting multiple sclerosis – case report Pavel Hradilek
EP1753 CD62L as a PML risk stratification marker: a 4 years prospective study Béatrice S. Pignolet
EP1754 Severe disease reactivation in two Multiple Sclerosis patients after Natalizumab withdrawal was not halted by monthly administrations of Cyclophosphamide – Two case reports Alice Mariottini
EP1755 A case of listeriosis in a multiple sclerosis patient treated with alemtuzumab: a strict clinical and laboratory monitoring can help to make early diagnosis and avoid related meningitis Lucia Moiola
EP1756 Multiple Sclerosis risk perception and risk acceptance for Brazilian patients Denis Bernardi Bichuetti
EP1757 Feasibility of online risk-based monitoring by patients: the Natalizumab case Esther M.J. Van Noort
EP1758 How to treat patients after Natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study Marinella Clerico
EP1759 A case report of asymptomatic progressive multifocal leukoencephalopathy Yinan Zhang
EP1760 Favorable evolution post hematologous stem cell transplant after Primary central nervous system lymphoma in a Multiple Sclerosis under Natalizumab Agnès Fromont
EP1761 Rebound of disease activity after fingolimod withdrawal: can we predict it? Julio Dotor García-Soto
EP1762 Central and peripheral nervous system inflammation disease secondary to alemtuzumab therapy Frederico M.H. Jorge
EP1763 The First Reported Case of Autoimmune Hepatitis Following Alemtuzumab Therapy for Multiple Sclerosis Luke J.W. Canham
EP1764 Correlation of global and regional brain volume changes with disease activity, cognition and disability in a 2-year follow-up of 60 Finnish MS patients Katariina Hänninen
EP1765 Stability of maximal oxygen uptake (V̇O2max) and clinical symptoms over one year in Multiple Sclerosis Liam P. Kelly
EP1766 The effect of quantitative magnetic resonance imaging (QMRI) on no evidence of disease activity (NEDA) status in multiple sclerosis clinical practice: A multicentre retrospective longitudinal study Heidi Beadnall
EP1767 Creating a healthcare claims-based adaptation of Kurtzke Functional Systems Scores for assessing multiple sclerosis severity and progression Hoa Van Le
EP1768 Multiple sclerosis with pattern III lesions successfully treated with mitoxantrone Thomas Grüter
EP1769 Patient reported quality of life and disability measures in the West Yorkshire Multiple sclerosis treatment programme Maruthi Vinjam
EP1770 Whole Brain Tract Disruption Better Explains Cognitive Decline in Multiple Sclerosis than Total Lesion Volume Tom Fuchs
EP1771 Persistent total suppression of T follicular regulatory lymphocytes in alemtuzumab-treated multiple sclerosis patients Marco Puthenparampil
EP1772 Evaluating the association between absolute lymphocyte count (ALC) after 6 months of dimethyl fumarate treatment and risk of relapse at one year Kyle E. Smoot
EP1773 Towards personalized therapy through extensive longitudinal follow-up using a multidisciplinary data infrastructure for people with MS : a-proof-of-concept study Liesbet M. Peeters
EP1774 Lateral ventricular atrophy measurements agree better than whole brain measures across centers and measurement techniques Michael G. Dwyer
EP1775 Real life efficacy and tolerability of Teriflunomide: multicentre study in Galicia (TERIGAL) Antonio Pato Pato
EP1776 MD1003 (High-Dose Biotin) for the Treatment of Progressive Multiple Sclerosis: Baseline Data and Results from a Cohort of Patients included in a Early Access Program David Brassat
EP1777 Characteristics and therapeutic management of patients with primary progressive multiple sclerosis – Data from a French multiple sclerosis population-based registry (the Multiple Sclerosis Registry in Lorraine Region) Jonathan Epstein
EP1778 Laquinimod regulates inflammatory gene induction in a human model of reactive astrogliosis Candice Chapouly
EP1779 An open label, single arm, phase II futility trial of Domperidone treatment in secondary progressive MS. Results of the first stage of the trial Marcus Koch
EP1780 Effect of MD1003 (High-Dose Biotin) in Spinal Progressive Multiple Sclerosis (MS-SPI): EDSS Sub-scores Ayman Tourbah
EP1781 Identification of main inclusion criteria of chronic progressive multiple sclerosis clinical trials: a review Nicolas Dubuisson
EP1782 In-depth profiling of immune-regulatory network alterations during sequential treatment with natalizumab and fingolimod – results of the ToFingo successor study Luisa Klotz
EP1783 Long-term Outcomes in Patients With Progressive Forms of Relapsing MS Treated With Teriflunomide: Patient-Level Data From the TEMSO and TOWER Extension Studies and the Real-World Setting Flavia Nelson
EP1784 Biotin in Multiple Sclerosis in clinical practice: a cohort of 154 patients Agnès Fromont
EP1785 A case of acute fulminant multiple sclerosis treated with alemtuzumab Francesca Gobbin
EP1786 Sleep and Fatigue Features in Multiple Sclerosis Patients on Alemtuzumab Treatment Barbara Barun
EP1787 No evidence of disease activity in anti–JC virus seronegative patients with early relapsing-remitting multiple sclerosis treated with natalizumab: a prespecified 2-year analysis of STRIVE Jai Perumal
EP1788 capillary leak syndrome in neuromyelitis optica treated with rituximab Rocio Hernandez Clares
EP1789 The national incidence of PML in Sweden, 1988 - 2013 Ellen Iacobaeus
EP1790 The therapeutic management of patients with Multiple Sclerosis in France: an analysis of the EGB database Bruno Detournay
EP1791 Use of complementary and alternative medicine in Hispanic patients with multiple sclerosis Andres Barboza
EP1792 A multi-centRE observational analysiS of PErsistenCe to Treatment in the new MS era: the RESPECT study Luca Prosperini
EP1793 Tolerability and persistence in therapy with PEGylated-IFN: results from a multicentric observational study in Italy Pietro Annovazzi
EP1794 Bridging the Gap- Challenges in Switching from Fingolimod to Alemtuzumab Mo Hu
EP1795 Neuromyelitis Optica Spectrum disorders: recurrence of relapses after suspension of immunosuppressive therapy in venezuelan patients Ibis Soto
EP1796 How neurologists approach the therapeutic choice in multiple sclerosis: preliminary results of an Italian survey Eleonora Minacapelli
EP1797 Factors influencing disease modifying therapy prescribing rates and practices: a qualitative study of neurologists and nurses Elaine Cameron
EP1798 Natalizumab Treatment is Associated with Improved Patient-Reported Outcomes in the Treatment of Multiple Sclerosis: Results from a Systematic Literature Review Kavita V. Nair
EP1799 REALMS Study: A non-interventional retrospective, multicenter study to evaluate the effectiveness of fingolimod therapy in real-life clinical practice in patients with relapsing-remitting multiple sclerosis (RRMS) in Portugal Sónia Batista
EP1800 Bicycle ergometry does not improve verbal memory in mild relapsing remitting MS - results of a RCT Christoph Heesen
EP1801 Treatment patterns of disease modifying therapies in MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) Bernd C. Kieseier
EP1802 The effect of Pilates training and massage therapy on plasma serum levels of IL_17 and IFNβ as pro- inflammatory cytokines in patients with Multiple Sclerosis (MS) Kaveh Mehrvar
EP1803 Early MRI Findings During Disease Rebound in a Natalizumab-Treated MS Patient and Follow-up During Transition to Alemtuzumab Jeffrey L. Gross
EP1804 Success of a CME-Certified Patient-Physician Video Vignette in Improving Knowledge of Clinical Factors for the Personalization of Treatment Selection in MS Among Neurologists Thomas F. Finnegan
EP1805 Patient Reported Adherence and Treatment Satisfaction in Irish Relapsing Remitting Multiple Sclerosis Patients treated with Fingolimod Niamh Murphy
EP1806 Comparison of injection site reactions and flu-like symptoms between users of peginterferon beta-1a and subcutaneous interferon beta-1a among persons with multiple sclerosis in the New York State Multiple Sclerosis Consortium Bianca Weinstock-Guttman
EP1807 BetaEval Global: prospective, non-interventional, multinational, observational cohort study of patients using BETACONNECT Francesco Patti
EP1808 Validation of the English translation of the Swedish Symptom Frequency Intensity and Distress (SFID) scale in persons with multiple sclerosis (PwMS) on interferon beta therapy Courtney Sarah Casserly
EP1809 Efficacy and treatment satisfaction after switching therapy in patients with relapsing-remitting multiple sclerosis: the multicentre, observational SURFINIA study Dario Cuomo
EP1810 Knee flexor muscle strength is related to gait performance in women with multiple sclerosis but not for healthy women Cintia Ramari
EP1811 Therapeutic benefit of uncobotulinum toxin A for the spasticity of the triceps surae in patients with multiple sclerosis: an observational study on gait spatiotemporal parameters Emilie Leblong
EP1812 Low Rates of Disease-Modifying Therapy Initiation and Switching After Steroid Treatment of Patients With MS: Treatment Patterns From a US Retrospective Claims-Based Study Marie Sanchirico
EP1813 Managing the transition to secondary progressive multiple sclerosis: a scoping review Andrea Giordano
EP1814 Does dalfampridine trigger or worsen trigeminal neuralgia in multiple sclerosis patients? Sila Usar Incirli
EP1815 Effect of Fampridine on the manual functions of patients with Multiple Sclerosis: Difference between cerebellar and pyramidal dysfunction Turhan Kahraman
EP1816 Effect of a standardized physical therapy program on objective and subjective balance in people with multiple sclerosis: a single- group, pretest-posttest study Carme Santoyo
EP1817 Physical Activity and Sedentary Behavior in MS: Impact on Dissociable Correlates of Cognitive Functioning Ruchika Shaurya Prakash
EP1818 Virtual reality training or physical activity? Which one is more effective in reducing pain among persons with multiple sclerosis? A Randomized controlled trial Shahnaz Shahrbanian
EP1819 Safety and efficacy of Botulinum toxin A in MS patients with intractable chronic Migraine Sasan Kazemian
EP1820 Cognitive problems in people with Multiple sclerosis: A mixed methods study on the provision and perceived effectiveness of cognitive rehabilitation Roshan das Nair
EP1821 De Novo Convulsive status epilepticus in multiple sclerosis patients treated with Dalfampridine Emilie Panicucci
EP1823 A New Cognitive-Linguistic Patient Report Tool: Correlation With the BICAMS Lori Kostich
EP1824 At-Home Transcranial Direct Current Stimulation (tDCS) Improves Mood in Multiple Sclerosis: Results from a Randomized, Sham-Controlled Trial Michael Shaw
EP1825 Investigation of the effects of computer assisted cognitive rehabilitation in multiple sclerosis patients: A randomised-controlled study Aysun Soysal
EP1826 Implementing cognitive rehabilitation for people with MS: Translating research into clinical practice Roshan das Nair
EP1827 Changes in activities of daily living by Fampyra Jelka Jansa
EP1828 Does mindfulness, meditation and progressive muscle relaxation reduce stress in people with Multiple Sclerosis? Susan Agland
EP1829 The effectiveness of a diverse manner of Functional Electrical Stimulation on balance, gait and quality of life in people with Multiple Sclerosis Terezie Prokopiusova
EP1830 Psychopathological symptoms have a profound effect on the quality of life of multiple sclerosis patients Tamás Biernacki
EP1831 How to improve self-management in multiple sclerosis? Directions of psychological interventions Maciej Wilski
EP1832 The Relationship Between Diagnosis Acceptance, Self-Concept, and Mental Health Outcomes In Individuals With Multiple Sclerosis Natalie K. Ward
EP1833 Effects of physical training on multiple sclerosis patients: a longitudinal study Matteo Ponzano
EP1834 Effects of multilateral exercises on motor skills in multiple sclerosis: a longitudinal study Luca Beratto
EP1835 Efficacy of Daclizumab Beta vs Intramuscular Interferon Beta-1a on Patient-Reported Outcomes Across Patient Demographic and Disease Activity Subgroups in DECIDE Eva Havrdova
EP1836 Improvement of quality of life and its relationship to neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with Natalizumab: A 3-years follow-up multicentric study Vincent Planche
EP1837 Energy expenditure of normal and fast walking in multiple sclerosis Lior Frid
EP1838 A mapping study to compare the educational offerings for patients in the fields of multiple sclerosis and HIV in Europe and Canada Peter Rieckmann
EP1839 Relationship between Social Support and perception of cognitive difficulties in people with Multiple Sclerosis Sandra Vanotti
EP1840 Longitudinal changes in mental toughness, sleep disturbances, and physical activity in patients with multiple sclerosis (MS) Dena Sadeghi Bahmani
EP1841 A three month interim analysis of quality of life in patients with relapsing remitting multiple sclerosis in the UK: the Patient Reported Outcomes with Fingolimod in Local Experience (PROFILE) study Michel Kroes
EP1842 Gait and physiotherapy: effectiveness of a physiotherapy circuit training on the ability to walk and quality of live in a multiple sclerosis´ s patients Anabel Granja Domínguez
EP1843 The impact of nurse advisors and online advice services on treatment adherence in multiple sclerosis (MS) Amelie Altenbuchner
EP1844 Fatigue management: Occupational Therapy intervention in Multiple Sclerosis for Argentinean population Maria Laura Saladino
EP1845 Dynamic contributors to low quality of life in MS along the disease course Sara Llufriu
EP1846 The 24 Hour Exercise Marathon for Multiple Sclerosis – to promote benefits of regular physical activity among patients and their supporters Klara Novotna
EP1847 Altered brain connectivity and its changes after physiotherapy in people with multiple sclerosis Marie Prochazkova
EP1848 Dance for health: The preliminary effects of a dance-intervention on cognition and hippocampal activation in patients with MS Marijn Huiskamp
EP1849 Brain atrophy in multiple sclerosis could be ameliorated by aerobic exercise Lina Savsek
EP1850 Fingolimod reduces the clinical expression of active demyelinating lesions in MS Elisabetta Signoriello